Bioreactors for development of tissue engineered heart valves

Joel L. Berry, Julie A. Steen, J. Koudy Williams, James E. Jordan, Anthony Atala, James J. Yoo

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Millions of people worldwide are diagnosed each year with valvular heart disease, resulting in hundreds of thousands of valve replacement operations. Prosthetic valve replacements are designed to correct narrowing or backflow through the valvular orifice. Although commonly used, these therapies have serious disadvantages including morbidity associated with long-term anticoagulation and limited durability necessitating repeat operations. The ideal substitute would be widely available and technically implantable for most cardiac surgeons, have normal hemodynamic performance, low risk for structural degeneration, thrombo-embolism and endocarditis, and growth potential for pediatric patients. Tissue engineered heart valves hold promise as a viable substitute to outperform existing valve replacements. An essential component to the development of tissue engineered heart valves is a bioreactor. It is inside the bioreactor that the scaffold and cells are gradually conditioned to the biochemical and mechanical environment of the valve to be replaced.

Original languageEnglish
Pages (from-to)3272-3279
Number of pages8
JournalAnnals of Biomedical Engineering
Volume38
Issue number11
DOIs
StatePublished - Nov 1 2010
Externally publishedYes

Fingerprint

Bioreactors
Tissue
Pediatrics
Hemodynamics
Orifices
Prosthetics
Scaffolds
Durability

Keywords

  • Bioreactor
  • Endothelial cells
  • Heart valves
  • Preconditioning
  • Valvular cells

ASJC Scopus subject areas

  • Biomedical Engineering

Cite this

Berry, J. L., Steen, J. A., Koudy Williams, J., Jordan, J. E., Atala, A., & Yoo, J. J. (2010). Bioreactors for development of tissue engineered heart valves. Annals of Biomedical Engineering, 38(11), 3272-3279. https://doi.org/10.1007/s10439-010-0148-6

Bioreactors for development of tissue engineered heart valves. / Berry, Joel L.; Steen, Julie A.; Koudy Williams, J.; Jordan, James E.; Atala, Anthony; Yoo, James J.

In: Annals of Biomedical Engineering, Vol. 38, No. 11, 01.11.2010, p. 3272-3279.

Research output: Contribution to journalArticle

Berry, JL, Steen, JA, Koudy Williams, J, Jordan, JE, Atala, A & Yoo, JJ 2010, 'Bioreactors for development of tissue engineered heart valves', Annals of Biomedical Engineering, vol. 38, no. 11, pp. 3272-3279. https://doi.org/10.1007/s10439-010-0148-6
Berry JL, Steen JA, Koudy Williams J, Jordan JE, Atala A, Yoo JJ. Bioreactors for development of tissue engineered heart valves. Annals of Biomedical Engineering. 2010 Nov 1;38(11):3272-3279. https://doi.org/10.1007/s10439-010-0148-6
Berry, Joel L. ; Steen, Julie A. ; Koudy Williams, J. ; Jordan, James E. ; Atala, Anthony ; Yoo, James J. / Bioreactors for development of tissue engineered heart valves. In: Annals of Biomedical Engineering. 2010 ; Vol. 38, No. 11. pp. 3272-3279.
@article{e16965242690458883d2adb6955fcfb4,
title = "Bioreactors for development of tissue engineered heart valves",
abstract = "Millions of people worldwide are diagnosed each year with valvular heart disease, resulting in hundreds of thousands of valve replacement operations. Prosthetic valve replacements are designed to correct narrowing or backflow through the valvular orifice. Although commonly used, these therapies have serious disadvantages including morbidity associated with long-term anticoagulation and limited durability necessitating repeat operations. The ideal substitute would be widely available and technically implantable for most cardiac surgeons, have normal hemodynamic performance, low risk for structural degeneration, thrombo-embolism and endocarditis, and growth potential for pediatric patients. Tissue engineered heart valves hold promise as a viable substitute to outperform existing valve replacements. An essential component to the development of tissue engineered heart valves is a bioreactor. It is inside the bioreactor that the scaffold and cells are gradually conditioned to the biochemical and mechanical environment of the valve to be replaced.",
keywords = "Bioreactor, Endothelial cells, Heart valves, Preconditioning, Valvular cells",
author = "Berry, {Joel L.} and Steen, {Julie A.} and {Koudy Williams}, J. and Jordan, {James E.} and Anthony Atala and Yoo, {James J.}",
year = "2010",
month = "11",
day = "1",
doi = "10.1007/s10439-010-0148-6",
language = "English",
volume = "38",
pages = "3272--3279",
journal = "Annals of Biomedical Engineering",
issn = "0090-6964",
publisher = "Springer Netherlands",
number = "11",

}

TY - JOUR

T1 - Bioreactors for development of tissue engineered heart valves

AU - Berry, Joel L.

AU - Steen, Julie A.

AU - Koudy Williams, J.

AU - Jordan, James E.

AU - Atala, Anthony

AU - Yoo, James J.

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Millions of people worldwide are diagnosed each year with valvular heart disease, resulting in hundreds of thousands of valve replacement operations. Prosthetic valve replacements are designed to correct narrowing or backflow through the valvular orifice. Although commonly used, these therapies have serious disadvantages including morbidity associated with long-term anticoagulation and limited durability necessitating repeat operations. The ideal substitute would be widely available and technically implantable for most cardiac surgeons, have normal hemodynamic performance, low risk for structural degeneration, thrombo-embolism and endocarditis, and growth potential for pediatric patients. Tissue engineered heart valves hold promise as a viable substitute to outperform existing valve replacements. An essential component to the development of tissue engineered heart valves is a bioreactor. It is inside the bioreactor that the scaffold and cells are gradually conditioned to the biochemical and mechanical environment of the valve to be replaced.

AB - Millions of people worldwide are diagnosed each year with valvular heart disease, resulting in hundreds of thousands of valve replacement operations. Prosthetic valve replacements are designed to correct narrowing or backflow through the valvular orifice. Although commonly used, these therapies have serious disadvantages including morbidity associated with long-term anticoagulation and limited durability necessitating repeat operations. The ideal substitute would be widely available and technically implantable for most cardiac surgeons, have normal hemodynamic performance, low risk for structural degeneration, thrombo-embolism and endocarditis, and growth potential for pediatric patients. Tissue engineered heart valves hold promise as a viable substitute to outperform existing valve replacements. An essential component to the development of tissue engineered heart valves is a bioreactor. It is inside the bioreactor that the scaffold and cells are gradually conditioned to the biochemical and mechanical environment of the valve to be replaced.

KW - Bioreactor

KW - Endothelial cells

KW - Heart valves

KW - Preconditioning

KW - Valvular cells

UR - http://www.scopus.com/inward/record.url?scp=78149284538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149284538&partnerID=8YFLogxK

U2 - 10.1007/s10439-010-0148-6

DO - 10.1007/s10439-010-0148-6

M3 - Article

C2 - 20820920

AN - SCOPUS:78149284538

VL - 38

SP - 3272

EP - 3279

JO - Annals of Biomedical Engineering

JF - Annals of Biomedical Engineering

SN - 0090-6964

IS - 11

ER -